Fax: (011)961 1 747 144
Locally advanced breast cancer†
Treatment guideline implementation with particular attention to low- and middle-income countries
Article first published online: 3 OCT 2008
Copyright © 2008 American Cancer Society
Supplement: Guidelines for International Breast Health and Cancer Control–Implementation
Volume 113, Issue Supplement 8, pages 2315–2324, 15 October 2008
How to Cite
El Saghir, N. S., Eniu, A., Carlson, R. W., Aziz, Z., Vorobiof, D., Hortobagyi, G. N. and on behalf of the Breast Health Global Initiative Systemic Therapy Focus Group (2008), Locally advanced breast cancer. Cancer, 113: 2315–2324. doi: 10.1002/cncr.23836
Complete financial disclosures are presented at the end of this article.
- Issue published online: 3 OCT 2008
- Article first published online: 3 OCT 2008
- Manuscript Accepted: 24 JUN 2008
- Manuscript Received: 10 JUN 2008
- The Breast Health Global Initiative Global Summit
- Bristol-Myers Squibb Company
- Ethicon Endo Surgery, Inc.
- GE Healthcare
- F. Hoffmann-La Roche AG
- Novartis Oncology
- Pfizer Inc.
- 11GreeneFL,PageDL,FlemingID, et al, eds. AJCC Cancer Staging Manual,6th ed. New York, NY: Springer-Verlag; 2002.
- 15National Comprehensive Cancer Network (NCCN). Breast Cancer. 2008 V2.2 Available at:http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed on June 10, 2008.
- 26National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21: 4165–4174., , , et al;
- 29Press release: neoadjuvant and adjuvant systemic therapy for breast cancer give equivalent survival, study finds. J Natl Cancer Inst. 2005; 97: 157..
- 32Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup Trial 0100 (SWOG-8814) [abstract]. Proc ASCO. 2002; 21: 37a., , , et al.
- 33The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004; 22: 2294–2302., , , et al.
- 40Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 3676–3685., , , et al.
- 41Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007; 13: 228–233., , , et al.
- 44Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: toxicity data from North Central Cancer Treatment Group phase III trial N9831 [abstract]. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2006; 24(18S). Abstract 523., , , et al.
- 49IMPACT Trialists' Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double- blind randomized trial. J Clin Oncol. 2005; 23: 5108–5116., , , et al;
- 50Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006; 106: 2095–2103., , , et al.
- 51Neoadjuvant endocrine therapy in LABC. In: SilvaO,ZurridaS, eds. Breast Cancer: A Practical Guide,3rd ed. New York, NY: Elsevier; 2005: 251–253., .
- 52Locally advanced breast cancer (T3 and T4), inflammatory and recurrent tumors. In: ChaoKSC,BradyLW, eds. Radiation Oncology Management Decisions,2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1999: 369–377., , .
- 55Breast health program in Kenya. Presented at the Breast Health Global Initiative Global Summit, Budapest, Hungary, October 1-4, 2007..
- 56Drug Prices and Pharmaceuticals. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York, NY: Random House; 2004..
- 57World Health Organization. Essential Medicines. WHO Model List, 2005. Available at:http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf. Accessed on June 10, 2008.
- 58US Food and Drug Administration. Drug Patents. FDA website. Available at:http://www.fda.gov/default.htm). Accessed on June 10, 2008.
- 59Milt Freudenheim. As Drug Patents End, Costs for Generics Surge. New York Times. Friday, December 27, 2002.
- 61National Institutes of Health. Trastuzumab for 6 months or 1 year in treating women with nonmetastatic breast cancer that can be removed by surgery. National Institutes of Health, October 2007. Available at:http://clinicaltrials.gov/show/NCT00381901. Accessed on June 10, 2008.
- 62PHARE, shining an academic light on research in Europe. Cancer World. 2006. Available at:http://www.cancerworld.org/CancerWorld/getStaticModFile.aspx?id=1181. Accessed on June 10, 2008..